GENEVA, SWITZERLAND--(Marketwire - September 07, 2010) - Addex Pharmaceuticals / Addex Awarded
Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced
Dyskinesia in Parkinson's Disease processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 8 September 2010 - Allosteric modulation company
Pharmaceuticals Ltd (SWISS: ADXN) announced today that it has been
$900,000 grant from The Michael J. Fox Foundation (MJFF) to help fund a
study of ADX48621 for the treatment of Parkinson's disease levodopa-
dyskinesia (PD-LID). Patients with PD can live 10-20 years after
however, LID is a leading cause of disability in this growing
"People with Parkinson's report that the side-effects of levodopa
one of the most difficult aspects of living with the disease. We
ADX48621 has the potential to improve the quality of life for patients
from the undesirable effects of long-term dopamine replacement," said
Hood, CEO, The Michael J. Fox Foundation. "ADX48621 targets a
mechanism that our Foundation has been investing in since 2005.
enthusiastic about funding this clinical work and the hope that it may
ADX48621 is a metabotropic glutamate receptor 5 (mGluR5) negative
modulator (NAM). It already has successfully completed Phase I testing in
studies involving a total of 130 patients, including older healthy
Phase II study of ADX48621 to treat PD-LID is expected to start in the
EU during the fourth quarter of 2010.
"We are honored to receive this grant from The Michael J. Fox
supporting ADX48621 development," said Vincent Mutel, CEO of Addex.
reduction in both major components of LID, which we observed after
ADX48621 to non-human primates with LID, has not been reported with other
on the market or in development. As a result, we believe that it could
the first drug capable of alleviating all LID symptoms."
Levodopa and dopamine agonists are effective treatments for the
symptoms of Parkinson's disease; but long-term levodopa use results
emergence of side effects, especially abnormal involuntary movement,
levodopa-induced dyskinesia or LID. Statistics show that half of
develop LID during the first five years of treatment. The two main
LID are chorea and dystonia. Chorea is manifest as sudden rapid
movements. Dystonia is manifest as slow writhing type movements and
muscle contractions, which can be painful.
In addition to reducing chorea, the stereotypical trembling often
with PD patients, ADX48621 is the first drug-candidate to effectively
dystonia in the non-human primate "MPTP model" of PD-LID.
mGluR5 inhibition reduces signaling activity of the neurotransmitter
The loss of dopamine producing cells observed as a result of Parkinson's
leads to excess of glutamatergic stimulation in the brain's
pathway. The mGluR5 are found abundantly in the striatum. Because most
PD work via the dopaminergic system, inhibition of mGluR5 could provide a
and complementary treatment option for PD and PD-LID. Indeed, published
shows that ADX48621 and other mGluR5 inhibitors have reduced LID and
anti-Parkinsonian effects in animal models of PD-LID and Parkinson's
respectively. In addition, one small clinical study already has shown
mGluR5 inhibition reduced LID symptoms in humans with PD-LID.
The Michael J. Fox Foundation was founded in 2000. The Michael J. Fox
for Parkinson's Research is dedicated to ensuring the development of a
Parkinson's disease through an aggressively funded research agenda.
Foundation has funded almost $200 million in research to date.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops
modulators for human health and is focused on validated therapeutic
diseases of the central nervous system, metabolic disorders and
Subject to regulatory approvals, Phase II clinical trials are expected to
soon in four indications for two lead products: ADX48621, an mGluR5
allosteric modulator (NAM), in dystonia and Parkinson's disease levodopa-
dyskinesia (PD-LID); and ADX71149, an mGluR2 positive allosteric
(PAM), in schizophrenia and anxiety. A third product, ADX71943, GABA-B
PAM with potential for chronic pain, is scheduled to enter Phase I
2011. In addition, Merck & Co., Inc. has licensed rights to two
products: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for
Additional preclinical discovery stage programs include: mGluR2 NAM; GLP1R
IL1R1 NAM; and TNFR1 NAM. Roche Venture Fund and SR-One, corporate
of GlaxoSmithKline, are investors in Addex.
Investor Relations & Communications
+41 22 884 15 11
Disclaimer: The foregoing release may contain forward-looking statements
can be identified by terminology such as "not approvable",
"believes", "believe", "will", "remained open to exploring", "would",
or similar expressions, or by express or implied discussions regarding
Pharmaceuticals Ltd, its business, the potential approval of its
regulatory authorities, or regarding potential future revenues from
products. Such forward-looking statements reflect the current views of
Pharmaceuticals Ltd regarding future events, future economic
prospects, and, by their very nature, involve inherent risks and
both general and specific, whether known or unknown, and/or any other
that may materially differ from the plans, objectives, expectations,
and intentions expressed or implied in such forward-looking statements.
in particular cause actual results with allosteric modulators of mGluR2,
mGluR5, mGluR7 or other therapeutic targets to be materially different
future results, performance or achievements expressed or implied by
statements. There can be no guarantee that allosteric modulators of
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or
regulatory authority. Nor can there be any guarantee that allosteric
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will
particular levels of revenue (if any) in the future. In particular,
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5,
or other therapeutic targets could be affected by, among other
unexpected actions by our partners, unexpected regulatory actions or
government regulation generally; unexpected clinical trial results,
unexpected new clinical data and unexpected additional analysis of
clinical data; competition in general; government, industry and general
pricing pressures; the company's ability to obtain or maintain patent or
proprietary intellectual property protection. Should one or more of these
or uncertainties materialize, or should underlying assumptions prove
actual results may vary materially from those anticipated, believed,
or expected. Addex Pharmaceuticals Ltd is providing the information in
press release as of this date and does not undertake any obligation to
any forward-looking statements contained in this press release as a
new information, future events or otherwise, except as may be
--- End of Message ---
12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE